Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 02 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2022.
- 02 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated